TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03185923
Drug: TCM plus conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were treated with antibiotics according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.~qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome in 28 treatment days.~zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome in 28 treatment days.~qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome in 28 treatment days.~shenmai injection（Sichuan chuanda west China Pharmaceutical Co., Ltd.）,15ml/ ampulla, 10～60ml each time (when needed), for yin exhausted syndrome in 28 treatment days.~shenfu injection（Sanjiu Medical \& Pharmaceutical Co., Ltd.）,10ml/ ampulla, 50～100ml each time (when needed), for yang exhausted syndrome in 28 treatment days.
Study: NCT03185923
Drug: TCM placebo plus conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were treated with antibiotics according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.~placebo qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome every day in 28 treatment days.~placebo zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome every day in 28 treatment days.~placebo qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome every day in 28 treatment days.
Study: NCT00761358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02954055
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm B
Study: NCT02954055
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm B
Study: NCT00459264
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid oral solution 2.5mg/5ml daily for up to 3 years
Study: NCT00459264
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for folic acid oral solution (2.5mg/5ml)
Study: NCT00361621
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously on day 1 of a 21-day cycle for 6 cycles
Study: NCT00361621
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravenously on day 1 of a 21-day cycle for 6 cycles
Study: NCT01316978
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single 2 x 100 mg dose of an experimental Ibuprofen Fast Melt Orodispersible Tablet administered orally, with a 7-day washout between visits
Study: NCT01316978
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single 200 mg Nurofen Meltlets Orodispersible Tablet administered orally, with a 7-day washout between visits
Study: NCT01316978
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single 2 x 100 mg dose of Junior Strength Motrin Chewable Tablet administered orally, with a 7-day washout between visits
Study: NCT04674722
Drug: Injection of 99mTc-NM-02
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer
Study: NCT04674722
Drug: Injection of 188Re-NM-02
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Patient will be injected with microdose (\<100ug) of 188Re-NM-02 radionuclide therapy
Study: NCT01429779
Drug: Movicol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movicol® in sachets of 13,81 gram each. One sachet consists of 13,125 gr Macrogol 3350, 178,5 mg Sodium bicarbonate, 350,7 mg Sodium chloride and 46,6 mg Potassium chloride. Administration of 1 sachet of Movicol® daily during one week preoperatively and 2 sachets of Movicol® daily postoperatively.
Study: NCT04044664
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules.
Study: NCT00300456
Drug: ABT-335
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mg, daily, 12 weeks
Study: NCT00300456
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily, 12 weeks, see Arm Description for dosage information
Study: NCT00300456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily, 12 weeks, see Arm Description for placebo information
Study: NCT04914936
Drug: ACP-196
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 in Part 1, Part 2, and Part 3; and on Day 1 of Period 2 in Part 1, Day 5 of Period 2 in Part 2, and Day 1 and Day 9 of Period 2 in Part 3.
Study: NCT03099824
Drug: GC4711 Oral Capsule G-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 82 mg (1 capsule)
Study: NCT03099824
Drug: IV GC4419
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.
Study: NCT03099824
Drug: GC4711 Oral Capsule G-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 164 mg (2 capsules)
Study: NCT03099824
Drug: GC4711 Oral Capsule G-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 246 mg (3 capsules)
Study: NCT03099824
Drug: GC4711 Oral Capsule G-111
Approvals — FDA: no, EMA: no, PMDA: no
Description: 175 mg (1 capsule)
Study: NCT03099824
Drug: GC4711 Oral Capsule G-112
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 145 mg (1 capsule)
Study: NCT03099824
Drug: GC4711 Oral Capsule G-119
Approvals — FDA: no, EMA: no, PMDA: no
Description: 233 mg (1 capsule)
Study: NCT03099824
Drug: GC4711 Oral Capsule G-125
Normalized name: Charcoaid-G 125 MG/ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 233 mg (1 capsule)
Study: NCT03099824
Drug: IV GC4711
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC4711 will be infused IV as a single dose of 30 mg in 250 mL normal saline, totaling 251 mL, over a 60-minute period using a programmable pump.
Study: NCT01130818
Drug: GLPG0492
Approvals — FDA: no, EMA: no, PMDA: no
Description: single ascending doses, oral solution (25 to max. 120 mg/intake, 10 to 200 mg/mL)
Study: NCT01130818
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, oral solution
Study: NCT01130818
Drug: GLPG0492
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, solid formulation, 50 mg (2\*25 mg/capsule), after high fat breakfast
Study: NCT00852423
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL (tablets containing a FDC of 20 mg of artemether and 120 mg of lumefantrine) is manufactured by Novartis and has been extensively used in Africa for the treatment of uncomplicated malaria. AL was registered in Switzerland in 1999, has since received marketing authorisation in several endemic and non-endemic countries and it is WHO pre-qualified.
Study: NCT03885596
Drug: CA-008
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: CA-008 4.2 mg reconstituted in saline
Study: NCT03885596
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg IV at the onset of anesthesia
Study: NCT03885596
Drug: Acetaminophen IV
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g at the onset of anesthesia
Study: NCT03885596
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery
Study: NCT03885596
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg PO bid each day postoperative
Study: NCT00383188
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, once daily (QD) for 12 weeks
Study: NCT03523962
Drug: DuraPrep
Normalized name: DuraPrep
Approvals — FDA: no, EMA: no, PMDA: no
Description: The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ \[3M Health Care, St Paul, MN\], will be the commercial product used.
Study: NCT01611194
Drug: Sham control 1.2 atms
Approvals — FDA: no, EMA: no, PMDA: no
Description: The chamber will be compressed with air to 1.2 atm abs to simulate the active group. Participants will don a hood and breathe 21% oxygen (room air). Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
Study: NCT01053039
Drug: Intrathecal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
Study: NCT00001146
Drug: Ethyl Eicosapentaenoic Acid
Normalized name: Ethyl eicosapentaenoate
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00001146
Drug: OmegaBrite
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01227707
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 825 mg/m2 twice daily orally, 38 days
Study: NCT01227707
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Post-surgery adjuvant treatment: 100 mg/m2 iv on Days 1 and 2 of each 2-week cycle for 6 months
Study: NCT02699710
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid will be administered orally as tablet at a single dose of 5 mg.
Study: NCT02108223
Drug: fix dose r-FSH (Gonal-f)
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant follicle stimulation
Study: NCT02108223
Drug: r-LH supplementation
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant luteinizing hormone
Study: NCT02108223
Drug: r-FSH (Gonal-f)
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant follicle stimulation hormone
Study: NCT02699710
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be administered orally as tablet at a single dose of 7.5 mg.
Study: NCT04314674
Drug: %3 HS bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: After head fixation %3 HS bolus 3 ml/kg will be administered
Study: NCT04314674
Drug: %3 HS infusion 20 ml/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: After head fixation %3 HS 20 ml/h infusion will be administered
Study: NCT00005581
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005581
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02989662
Drug: Placebo - Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive 6 doses
Study: NCT03103412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02817243
Drug: SP2086
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
Study: NCT02817243
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
Study: NCT01855360
Drug: Tauroursodeoxycholic Acid and Doxycycline
Normalized name: Tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02709603
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo; 2 tablets 30 minutes before the procedure
Study: NCT01060696
Drug: Mefenamic acid or Hyoscine or placebo
Normalized name: salicylic acid Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefenamic acid 500 mg. single oral use 30 minutes before SIS Hyoscine 10 mg. single oral use 30 minutes before SIS Placebo single oral use 30 minutes before SIS
Study: NCT01966913
Drug: ICE chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals, Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance, Ifosfamide, 2400 mg/m²/d, For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle
Study: NCT02628704
Drug: Placebo (for selinexor)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar tablet manufactured to mimic selinexor tablet
Study: NCT00209092
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sequential Therapy: administration of capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) Concurrent Therapy: capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
Study: NCT00811057
Drug: 1 Magnesium Sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to this arm will receive a loading dose of 6gms intravenously followed by a maintenance dose of 2-4gm/hr, per physician discretion, until uterine quiescence is achieved. The Magnesium Sulfate dosage is then titrated down until discontinued per physician discretion.
Study: NCT00811057
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized to receive indomethacin will receive an initial 100mg per rectum X1, may repeat x1, and then 25 - 50mg orally every 6 hours over 48 hours as needed per physician discretion until uterine quiescence has been achieved.
Study: NCT02607943
Drug: Regular Insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
Study: NCT00748423
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NO in inhalation for 3 days
Study: NCT00748423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in inhalation for 3 days
Study: NCT00549445
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg daily
Study: NCT00549445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily
Study: NCT01301833
Drug: alpha-glucosidase inhibitor
Normalized name: Alpha-glucosidase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02774148
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive 1,00mg IV Acetaminophen every 8 hours until 3 doses have been received post-operatively.
Study: NCT02774148
Drug: PO Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive 1,000mg po Acetaminophen every 8 hours.
Study: NCT01813448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01612130
Drug: Placebo 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 100 mg of placebo orally, 1 hour prior to surgical procedures
Study: NCT01709656
Drug: celecoxib, Celebrex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-steroid anti-inflammatory drugs (NSAID):celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up
Study: NCT02663622
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Acute GVHD prophylaxis
Study: NCT02663622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml saline IV infusion.
Study: NCT02611232
Drug: Victoza®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
Study: NCT02611232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
Study: NCT00392678
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided
Study: NCT00392678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Salsalate
Study: NCT00380627
Drug: MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02112292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02809118
Drug: AM-111 0.4 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM-111 0.4 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
Study: NCT02809118
Drug: AM-111 0.8 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM-111 0.8 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
Study: NCT00443625
Drug: SK3530
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01844791
Drug: OCZ103-OS
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCZ103-OS is given in combination with chemotherapy each cycle
Study: NCT00509028
Drug: Conventional Asthma Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
Study: NCT00904111
Drug: Lidoderm®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
Study: NCT02055287
Drug: LY03004
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00904111
Drug: Placebo Topical Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
Study: NCT00114855
Drug: HYPOCOL®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03088527
Drug: RAD140
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD140 will be supplied as formulated drug-in-capsules for oral administration.
Study: NCT02008344
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily
Study: NCT02493335
Drug: Placebo orodispersible tablet twice daily
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02255955
Drug: 550 mg naproxen sodium and 30mg codeine
Normalized name: naproxen sodium 550 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative contramal consumption, pain intensity, side effects
Study: NCT02255955
Drug: 300 mg paracetamol and 30 mg codeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative contramal consumption, pain intensity, side effects
Study: NCT02255955
Drug: placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative contramal consumption, pain intensity, side effects
Study: NCT00798473
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 0.066 mg/kg (maximum 4 mg) given as a single intravenous infusion over ten minutes
Study: NCT00711412
Drug: Induction Therapy - Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two 21-day cycles will be given as induction. Capecitabine will be given at 1000 mg/m2 twice daily approximately 12 hours apart for 14 days, followed by seven days off.
Study: NCT00561288
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 1000 mg doses per day
Study: NCT00711412
Drug: Combination Therapy - Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two 21-day cycles will be given for combination therapy. Capecitabine will be given at 825 mg/m2 twice daily approximately 12 hours apart for five days (Monday through Friday) followed by two days off for 51/2 weeks.
Study: NCT04318444
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
Study: NCT02005588
Drug: amino acid chelated iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: the drug will be given to pregnant women 14-18 weeks' gestation who prove to have iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily. for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.